Retatrutide — ≥98% Research Peptide

The World's First Triple-Action Metabolic Peptide

First peptide that simultaneously activates GIP, GLP-1, AND glucagon receptors. The third target adds direct energy burning and fat breakdown.

Research Applications & Benefits

Doses Used in Published Studies

Literature values for laboratory reference only — not dosing guidance.

ModelDoseRouteDurationRef
Human, adults with obesity (Phase 2)1, 4, 8 or 12 mg (escalated from 2 or 4 mg)Subcutaneous, once weekly48 weeks[1]

Laboratory Handling

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315

Product Specifications

Compound
Retatrutide
CAS Number
2381089-83-2
Molecular Weight
4603.27 g/mol
HPLC Purity Specification
≥98%
Category
GLP-1 & Metabolic
Starting Price
$119.00 USD
Country of Origin
United States
Shipping
Cold-chain insulated packaging, fast domestic delivery
Payment
Card, ACH, and cryptocurrency (10% discount)

Quality & Verification

Retatrutide carries the purity specification shown above. Where a lot-specific CertikLabs Certificate of Analysis is available, the product page links its HPLC purity, LC-MS identity, and concentration results.

Frequently Asked Questions

Is Retatrutide suitable for human consumption?

No. Retatrutide is sold strictly for in-vitro laboratory research. It is not a drug, supplement, cosmetic, or food product and must not be administered to humans or animals.

What purity is Retatrutide?

Retatrutide carries a ≥98% HPLC purity specification. Check the product page for an available lot report.

How is Retatrutide shipped and stored?

Vials are shipped lyophilized in temperature-controlled packaging. Store unopened lyophilized peptide at −20°C; once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days.

Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.